The Economic Times

Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn Saldanha

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from its traditional generics-led model. The company is developing next-generation products targeting oncology and other complex diseases. Glenmark aims to become a global powerhouse in oncology within ten years. Artificial intelligence will significantly accelerate drug discovery and development processes.